Freedom Broker cuts NioCorp stock price target on funding dilution

Freedom Broker cut its NioCorp price target to $8.40 from $12.00 while maintaining a Buy rating, citing an estimated $489 million equity raise—about 90 million shares at an average $5.40 issue price—still needed before first production. The firm estimates the EXIM facility at 65% of upfront capital expenditures, consistent with management’s $1.2 billion–$1.3 billion indication; NioCorp shares were reported at $0.06, near their 52-week low of $0.05. Jefferies initiated coverage at Hold with a $4.70 target, while H.C. Wainwright reiterated Buy at $10.00; reported discussions with Lockheed Martin about scandium supply remain prospective.

Analysis

The key market risk is financing execution, not the analyst target reset: if project debt covers less than the assumed share of upfront capex, NioCorp may need more equity, accept worse terms, or delay development. Any of those outcomes can compound dilution and weaken the economics for existing shareholders. Conversely, an EXIM commitment would reduce funding uncertainty, but it would not by itself establish construction readiness, final project cost, or attractive returns.

There is a material data-integrity issue to resolve before trading: the article quotes NB at $0.06 while also discussing a roughly $5.40 assumed share-issue price and mult-dollar targets. These figures are not comparable without confirming split-adjustment, quote currency, and the filing’s share basis; do not infer dilution percentage or target upside from them. The claimed cash-over-debt position also does not demonstrate that the company can fund a capital-intensive project.

A Lockheed Martin supply discussion is strategically supportive but not yet evidence of a binding, material offtake contract; absent volumes, pricing, and duration, it should not change LMT earnings assumptions. Near term, financing announcements and verified share data dominate. Over 1–3 months, watch for EXIM terms, committed financing, and equity issuance details. Over 6–18 months, construction costs, permitting, and customer contracts determine whether strategic-mineral optionality converts to cash flow. The bullish thesis is falsified by funding terms materially below the stated coverage assumption, a larger or deeply discounted raise, or project delays/cost escalation.

Key Decisions for Investors

• NB: Avoid sizing a directional position off the quoted price targets until the $0.06 quote, share basis, and corporate-action history are reconciled against the 10-K and current market data.
• Treat NB as a financing-event watchlist name, not a validated undervaluation. Reassess only after verifying EXIM facility status and terms, remaining equity need, fully diluted share count, and any binding offtake economics.
• Do not trade LMT on the reported discussions alone; require confirmation of a signed agreement with disclosed or otherwise credible materiality before changing estimates.
• If already exposed to NB, stress-test dilution and delay scenarios rather than relying on analyst targets; a financing shortfall or discounted issuance is the clearest near-term thesis-breaker for the bullish case.